Skip to main content
. Author manuscript; available in PMC: 2017 Apr 15.
Published in final edited form as: Cancer Res. 2016 Feb 26;76(8):2432–2442. doi: 10.1158/0008-5472.CAN-15-2162

Figure 1. GBM cells are resistant to lapatinib but sensitive to CBL0137 and CBL0137 plus lapatinib.

Figure 1

Cells from xenografted GBM patient-derived tumor specimens, or a nonneoplastic brain specimen were treated with the indicated concentrations of lapatinib (Lap) and/or CBL0137 (137). Cell proliferation at the indicated time-points was normalized to the values from Day 0 [*, P<0.05; ***, P<0.001 with two-way ANOVA followed by Bonferroni’s posttest compared to Day 0; all values represent means ± SD].